196 related articles for article (PubMed ID: 37753076)
1. PD-1 blockade and radiotherapy combination for advanced Epstein-Barr virus-associated intrahepatic cholangiocarcinoma: a case report and literature review.
Liao CX; Deng CS; Liang X; Yang JC; Chen ZZ; Lin XY; Lin CF; Chen S; Wu SS
Front Immunol; 2023; 14():1239168. PubMed ID: 37753076
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
Huang YH; Zhang CZ; Huang QS; Yeong J; Wang F; Yang X; He YF; Zhang XL; Zhang H; Chen SL; Zheng YL; Deng R; Lin CS; Yang MM; Li Y; Jiang C; Kin-Wah Lee T; Ma S; Zeng MS; Yun JP
J Hepatol; 2021 Apr; 74(4):838-849. PubMed ID: 33212090
[TBL] [Abstract][Full Text] [Related]
3. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade.
Liu X; Yao J; Song L; Zhang S; Huang T; Li Y
J Immunother Cancer; 2019 Aug; 7(1):204. PubMed ID: 31383016
[TBL] [Abstract][Full Text] [Related]
4. Response to programmed cell death protein 1 antibody in patients with Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
He WZ; Huang YH; Hu WM; Wang F; Xu YX; Yi JH; Xue J; Yang YZ; Chao XY; Lin HB; Guo GF; Yun JP; Xia LP
Eur J Cancer; 2023 Nov; 194():113337. PubMed ID: 37862797
[TBL] [Abstract][Full Text] [Related]
5. The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma.
Chiang NJ; Hou YC; Tan KT; Tsai HW; Lin YJ; Yeh YC; Chen LT; Hou YF; Chen MH; Shan YS
Hepatol Int; 2022 Oct; 16(5):1137-1149. PubMed ID: 35780451
[TBL] [Abstract][Full Text] [Related]
6. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
[TBL] [Abstract][Full Text] [Related]
7. Case report: Long response to PD-1 blockade after failure of trastuzumab plus chemotherapy in advanced Epstein-Barr virus-associated gastric cancer.
Pan Y; Lu L; Liu H; Chen D; Han N; Yao R; Wang X; Gao X; Yu J; Chen L; Zhou F; Hao G; Lu Y; Li M; He G; Kang F; Li Z; Tang Y; Zhang J; Wei L; Nie Y
Front Immunol; 2022; 13():1003859. PubMed ID: 36353623
[TBL] [Abstract][Full Text] [Related]
8. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
Front Immunol; 2021; 12():705378. PubMed ID: 34526987
[TBL] [Abstract][Full Text] [Related]
9. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
[TBL] [Abstract][Full Text] [Related]
10. Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report.
Zhang Z; Zhang W; Wang H; Hu B; Wang Z; Lu S
Front Immunol; 2021; 12():744571. PubMed ID: 34603331
[TBL] [Abstract][Full Text] [Related]
11. Tumor-derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression.
Luo C; Xin H; Zhou Z; Hu Z; Sun R; Yao N; Sun Q; Borjigin U; Wu X; Fan J; Huang X; Zhou S; Zhou J
Hepatology; 2022 Oct; 76(4):982-999. PubMed ID: 35106794
[TBL] [Abstract][Full Text] [Related]
12. Programmed Cell Death Protein 1 Blockade Elicits Ongoing Remission in 2 Cases of Refractory Epstein-Barr Virus-Associated Metastatic Gastric Carcinoma.
Masetti M; Lindinger M; Lorenzen S
Oncol Res Treat; 2022; 45(6):375-379. PubMed ID: 35220300
[TBL] [Abstract][Full Text] [Related]
13. Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis.
Chao J; Wang S; Wang H; Zhang N; Wang Y; Yang X; Zhu C; Ning C; Zhang X; Xue J; Zhang L; Piao M; Wang M; Yang X; Lu L; Zhao H
Cancer Immunol Immunother; 2023 Nov; 72(11):3717-3726. PubMed ID: 37787790
[TBL] [Abstract][Full Text] [Related]
14. Prognostic roles of leptin-signaling proteins, PD-L1, and tumor-infiltrating lymphocytes in surgically-resected biliary tract cancers.
Byeon SJ; Chang MS; Cho HJ; Park JH; Kim KH; Park JH; Choi IS; Kim W; Han DS; Ahn HS; Heo SC
J Surg Oncol; 2023 Mar; 127(4):587-597. PubMed ID: 36367404
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study.
Zhu C; Li H; Yang X; Wang S; Wang Y; Zhang N; Wang Y; Xue J; Zhang L; Ning C; Yang X; Xun Z; Chao J; Long J; Sang X; Zhu Z; Zhao H
Cancer Immunol Immunother; 2023 Sep; 72(9):2949-2960. PubMed ID: 37247023
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of pembrolizumab in microsatellite instability-high locally advanced cholangiocarcinoma: a case report.
Toshida K; Itoh S; Yoshizumi T; Shimagaki T; Wang H; Kurihara T; Toshima T; Nagao Y; Harada N; Oki E; Nakamura Y; Yoshino T; Mori M
Clin J Gastroenterol; 2021 Oct; 14(5):1459-1463. PubMed ID: 34085164
[TBL] [Abstract][Full Text] [Related]
17. Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: A case report and literature review.
Zhang W; Luo C; Zhang ZY; Zhang BX; Chen XP
Front Immunol; 2022; 13():1079342. PubMed ID: 36700218
[TBL] [Abstract][Full Text] [Related]
18. Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma.
Dong Z; Liao B; Shen W; Sui C; Yang J
Dig Dis Sci; 2020 Feb; 65(2):480-488. PubMed ID: 31410753
[TBL] [Abstract][Full Text] [Related]
19. Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma.
Yang X; Lian B; Zhang N; Long J; Li Y; Xue J; Chen X; Wang Y; Wang Y; Xun Z; Piao M; Zhu C; Wang S; Sun H; Song Z; Lu L; Dong X; Wang A; Liu W; Pan J; Hou X; Guan M; Huo L; Shi J; Zhang H; Zhou J; Lu Z; Mao Y; Sang X; Wu L; Yang X; Wang K; Zhao H
BMC Med; 2024 Jan; 22(1):42. PubMed ID: 38281914
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
